Insulin: too much of a good thing is bad
H Kolb, K Kempf, M Röhling, S Martin - BMC medicine, 2020 - Springer
Background Insulin shares a limited physiological concentration range with other endocrine
hormones. Not only too low, but also too high systemic insulin levels are detrimental for body …
hormones. Not only too low, but also too high systemic insulin levels are detrimental for body …
[HTML][HTML] Therapy of type 2 diabetes
R Landgraf, J Aberle, AL Birkenfeld… - Experimental and …, 2019 - thieme-connect.com
The practical recommendations of the German Diabetes Society/Deutsche Diabetes
Gesellschaft (DDG) together with the German Society for Internal Medicine/Deutschen …
Gesellschaft (DDG) together with the German Society for Internal Medicine/Deutschen …
Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
Background Randomized trials demonstrated a lower risk of cardiovascular (CV) events with
sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at …
sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at …
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering …
Background In patients with type 2 diabetes and a high cardiovascular risk profile, the
sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have …
sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have …
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with …
F Persson, T Nyström, ME Jørgensen… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with
dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk associations with major …
dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk associations with major …
Real-world studies no substitute for RCTs in establishing efficacy
HC Gerstein, J McMurray, RR Holman - The Lancet, 2019 - thelancet.com
The trust that authors place in editors, and editors in reviewers, creates a precious
opportunity to strengthen manuscripts and advance science. The Lancet values deeply the …
opportunity to strengthen manuscripts and advance science. The Lancet values deeply the …
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: a nationwide …
A Norhammar, J Bodegård, T Nyström… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aims To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other
glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the …
glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the …
Rationale for timely insulin therapy in type 2 diabetes within the framework of individualised treatment: 2020 update
M Hanefeld, H Fleischmann, T Siegmund, J Seufert - Diabetes Therapy, 2020 - Springer
Type 2 diabetes is characterised by chronic hyperglycaemia and variable degrees of insulin
deficiency and resistance. Hyperglycaemia and elevated fatty acids exert harmful effects on …
deficiency and resistance. Hyperglycaemia and elevated fatty acids exert harmful effects on …
Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in …
T Nyström, J Bodegard, D Nathanson… - Diabetes, Obesity …, 2017 - Wiley Online Library
Aims To investigate the association of novel oral glucose‐lowering drugs (GLDs), compared
with that of insulin, with risk of all‐cause mortality, cardiovascular disease (CVD) and severe …
with that of insulin, with risk of all‐cause mortality, cardiovascular disease (CVD) and severe …
Worsening heart failure during the use of DPP-4 inhibitors: pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic …
M Packer - JACC: Heart Failure, 2018 - jacc.org
Abstract Although dipeptidyl peptidase (DPP)-4 inhibitors have been reported to have a
neutral effect on thromboembolic vaso-occlusive events in large-scale trials, they act to …
neutral effect on thromboembolic vaso-occlusive events in large-scale trials, they act to …